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OBJECTIVES This study evaluated the effects of oral therapy with coenzyme Q on echocardiographic and
hemodynamic indexes of left ventricular function and on quality of life in patients with
chronic left ventricular dysfunction.
BACKGROUND Coenzyme Q is a coenzyme for oxidative phosphorylation and an antioxidant and free radical
scavenger. It has been claimed to improve symptoms, quality of life, left ventricular ejection
fraction and prognosis in patients with cardiac failure.
METHODS Thirty patients with ischemic or idiopathic dilated cardiomyopathy and chronic left
ventricular dysfunction (ejection fraction 26 6 6%) were randomized to a double-blind
crossover trial of oral coenzyme Q versus placebo, each for 3 months. Right heart
pressures, cardiac output and echocardiographic left ventricular volumes were measured
at baseline and after each treatment phase, and quality of life was assessed using the
Minnesota “Living With Heart Failure” questionnaire. It was calculated that to
demonstrate an increase in left ventricular ejection fraction from 25% to 30% with a
standard deviation of 5% using 95% confidence intervals with a power of 80% we would
require 17 patients.
RESULTS Twenty-seven completed both treatment phases. There was no significant difference in left
ventricular ejection fraction, cardiac volumes or hemodynamic and quality of life indices after
treatment with coenzyme Q or placebo, although plasma coenzyme Q levels increased from
903 6 345 nmol/l21 to 2,029 6 856 nmol/l21.
CONCLUSIONS In patients with left ventricular dysfunction, treatment for three months with oral coenzyme
Q failed to improve resting left ventricular systolic function or quality of life despite an
increase in plasma levels of coenzyme Q to more than twice basal values. (J Am Coll Cardiol
1999;33:1549–52) © 1999 by the American College of Cardiology
Chronic heart failure is associated with significant morbidity
and mortality. It has been speculated that defective myocyte
energy production might be improved with mitochondrial
enzyme supplementation, therefore improving contractility
and clinical outcome.
Coenzyme Q (2,3-dimethoxy-5 methyl-6-decaprenyl-
1,4-benzoquinone) was first isolated from beef heart in 1957
(1). It is a vitamin-like fat-soluble quinone found in high
concentrations in the mitochondria of heart, liver and
kidney (2), where it is involved in electron and proton
transfer during oxidative phosphorylation (3). It is also an
antioxidant and free radical scavenger with membrane-
stabilizing properties (4,5). It has been postulated that its
depletion, which has been demonstrated in myocardial
biopsies (6,7), may contribute to heart failure (8), and that
it may be useful for treating a variety of conditions (9)
including angina pectoris, diastolic dysfunction and cardiac
failure. Several studies have claimed improvement in symp-
toms, quality of life, left ventricular ejection fraction and
prognosis of patients with cardiac failure after oral coen-
zyme Q (10–12). We believe that these lack credibility
because of small sample sizes, lack of controls and blinded
randomization and the use of inaccurate or outdated meth-
ods to assess ventricular function.
We report the results of a placebo-controlled double-
blind randomized crossover trial of coenzyme Q on resting
left ventricular function in patients with heart failure stabi-
lized on conventional vasodilator therapy.
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METHODS
Thirty patients, who were recruited from our heart failure
and transplant unit, had chronic heart failure (duration 41 6
35 months) and left ventricular dysfunction (ejection frac-
tion ,35% on echocardiography) for at least three months.
They were clinically stable on maximum tolerated doses of
angiotensin-converting enzyme (ACE) inhibitor therapy.
Twenty-four were taking digoxin, 28 frusemide and 25
hydralazine and/or nitrates.
They were between 18 and 75 years of age with ischemic
or idiopathic dilated cardiomyopathy. They were excluded if
they had obstructive valvular heart disease, renal (serum
creatinine .0.18 mmol/liter21) or hepatic (serum aspartate
or alanine aminotransaminase . upper limit of normal)
impairment, a history of alcohol or drug abuse or an
inadequate echocardiographic study, or if they were preg-
nant.
After informed consent and baseline echocardiography,
patients were randomized to blinded treatment with coen-
zyme Q (33 mg t.d.s.) or identical placebo therapy. After 12
weeks there followed a washout period of 1 week before they
were crossed to the alternate treatment arm for a further 12
weeks. Other therapy was altered only if indicated clinically.
Transthoracic echocardiograms were repeated after each
treatment phase and reviewed by four experienced sonog-
raphers blinded to the treatment protocol. Left ventricular
end-diastolic and end-systolic volumes were measured and
ejection fraction calculated using Simpson’s biplane method
(13).
To assess the reproducibility and interobserver variability
of echocardiographic measurement, two experienced echo-
cardiographers who were blinded to clinical condition in-
dependently assessed left ventricular end-diastolic and end-
systolic volume and ejection fraction in 15 unselected
patients whose left ventricular function varied from normal
to severely depressed. There was a strong linear correlation
between the observers (r 5 0.94, p , 0.001). There was a
small systematic difference in volume assessment (,10%)
and ejection fraction (12%). Bland and Altman analysis (14)
did not demonstrate exaggeration of error at either end of
the volume or ejection fraction spectrum.
Right heart catheterization was performed with a balloon
flotation (Swan-Ganz) catheter at baseline and at the end of
each treatment phase to measure right heart and mean
pulmonary capillary wedge pressures and cardiac output
using the thermodilution technique (15). Medications were
not withheld.
Quality of life was assessed using the Minnesota “Living
With Heart Failure” questionnaire (16) and routine bio-
chemistry, liver function tests and blood count examination
were performed at baseline and after each treatment phase.
Patients were reviewed each month.
Plasma coenzyme Q determination. Plasma coenzyme Q
levels were measured at baseline and at the end of each
treatment phase using high performance liquid chromatog-
raphy (17–19) with a reverse-phase C-18 column (20 to
25 cm, 5-mm particle size). The mobile phase was a 15:18
hexane:methanol solution which was delivered at 2 ml/
min21, with the samples measured at a wavelength of
280 nm. Blood was collected into lithium heparin tubes. A
coenzyme Q standard in phosphate buffer (0.05 mol/l, pH
7.4) was used at a concentration of 1181 nmol/liter21.
Coenzyme Q 9 in ethanol was used as the internal standard.
This was added to both the standard coenzyme Q and
plasma tubes before extraction. Coenzyme Q standards and
plasma samples (500 ml) were extracted with 2 ml of
methanol and 9 ml of hexane. The tubes were shaken
vigorously horizontally for 5 min and centrifuged for
10 min. The top hexane layer was evaporated under nitro-
gen in a 40°C water bath. The samples were then reconsti-
tuted into 500 ml of a 1:3 hexane:dichloromethane (H:D)
solution and applied to silica Sep-Pak (Waters Corp.,
Milford, Massachusetts) columns (690 mg) which had been
washed with 12.5 ml of the H:D solution. The columns
were then washed with 3.5 ml of the H:D solution, with
coenzymes Q 9 and Q 10 being retained on the column. The
coenzyme Q fraction was further eluted with 5 ml of the
H:D solution, evaporated under nitrogen and reconstituted
into 120 ml of ethanol for measurement by high perfor-
mance liquid chromatography. Eleven control subjects (each
with cholesterol levels within the reference range) were
assayed, giving a mean of 798 6 205 nmol/liter21.
Statistical methods. We compared echocardiographic and
hemodynamic data during treatment with coenzyme Q or
placebo with multivariate analysis of variance. We calculated
that to demonstrate an increase in left ventricular ejection
fraction from 25% to 30% with a standard deviation of 5%
using 95% confidence intervals with a power of 80% we
would require 17 patients. Quality of life scores with
coenzyme Q or placebo were compared with Friedman
two-way analysis of variance.
RESULTS
Thirty patients were randomized between April 1994 and
October 1995 (Table 1). All were stable clinically and on
ACE inhibitor therapy. Three did not complete the trial
(one died of heart failure while taking placebo and two
underwent cardiac transplantation because of persisting
symptoms). Echocardiographic and hemodynamic data are
shown in Table 2. Values on active treatment or differences
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
D 5 dichloromethane
H 5 hexane
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between baseline and active treatment did not differ signif-
icantly from those on placebo medication (Fig. 1).
Plasma levels of coenzyme Q at baseline and after each
treatment phase were available on 20 patients. After active
treatment these increased from 903 6 345 nmol/liter21
(baseline) to 2,029 6 856 nmol/liter21.
There was no difference in well-being or functional
capacity with coenzyme Q or placebo as assessed with the
Minnesota “Living With Heart Failure” questionnaire (16)
(p 5 0.22). The mean sum of all scores at baseline was
29.4 6 16.6 (median 23), on coenzyme Q 26.7 6 17.9
(median 22) and on placebo 26.5 6 18.7 (median 22).
Coenzyme Q was well tolerated and its use was associated
with no adverse effects, deterioration in renal or hepatic
function or alteration in hematologic parameters.
DISCUSSION
Folkers et al. suggested that coenzyme Q might be helpful
in those with cardiac failure because of its deficiency in the
myocardium and plasma of such patients (8). We studied
patients with chronic left ventricular dysfunction to deter-
mine if a dose of 100 mg daily would improve resting left
ventricular systolic function. All had chronic heart muscle
dysfunction, were clinically stable and were receiving ACE
inhibitor therapy in doses which were considered optimal or
were limited by postural hypotension or renal dysfunction.
Changes in treatment during the trial were avoided as far as
possible.
Coenzyme Q for 3 months produced no demonstrable
improvement in resting left ventricular ejection fraction
(Fig. 2), volumes (Table 2, Fig. 1) or quality of life scores
compared with placebo. The pathophysiology of heart
failure may be too complex to be explained simply by the
depletion of myocardial energy stores and therefore likely to
be reversed by coenzyme Q.
Study limitations. The dose and the duration of therapy
were similar to other studies and were sufficient to achieve a
greater than twofold increase in plasma levels of coenzyme
Q (20–22). Nevertheless, as we did not perform myocardial
biopsies we cannot be sure that myocardial stores were
replenished nor can we comment on whether beginning
coenzyme Q therapy earlier in the natural history of the
disease might have improved left ventricular function.
Although there is a degree of intraobserver variability in
echocardiographic measurements of cardiac volumes, this
was minimized by limiting interpretation to a few experi-
enced echocardiographers blinded to the treatment. All
studies were reviewed independently to establish uniformity
in reporting. We were concerned with the difficulty of
proving the null hypothesis but calculated that the study was
adequately powered to demonstrate an increase in left
ventricular ejection fraction by 5%.
Indexes of pump function such as left ventricular ejection
fraction and end-systolic volume are sensitive to loading
conditions. Although changes in doses of vasodilator ther-
apy during the trial were unavoidable in some patients, there
were no significant changes in pulmonary artery wedge
pressure or systemic vascular resistance in the treatment
groups.
Conclusions. In patients with chronic left ventricular dys-
function secondary to ischemic or idiopathic cardiomyopa-
thy taking maximal conventional therapy, treatment for 3
months with coenzyme Q failed to improve resting left
Table 1. Patient Demographics and Clinical Details
Number randomized 30
Mean age (yr) 55 6 11
Male 26 (87%)
Duration of heart failure (mo) 41 6 35
Dilated cardiomyopathy 23 (77%)
Ischemic cardiomyopathy 7 (23%)
Table 2. Echocardiographic and Hemodynamic Data
Baseline Coenzyme Q Placebo p <*
Left ventricular diastolic volume (ml) 220 6 72 209 6 75 220 6 68 0.16
Left ventricular systolic volume (ml) 167 6 54 149 6 61 155 6 58 0.26
Ejection fraction (%) 26 6 6 31 6 9 31 6 9 0.98
Cardiac index 2.7 6 0.7 2.9 6 0.7 2.9 6 0.7 0.46
Pulmonary wedge pressure (mm Hg) 16 6 6 16 6 7 16 6 7 0.40
Systemic vascular resistance (U) 16 6 4 15 6 4 15 6 5 0.24
*Multivariate analysis of variance coenzyme Q versus placebo, effect–order of treatment.
Figure 1. Box-and-whisker plots showing changes in values (delta
%, y axis) from baseline for (1) left ventricular systolic volumes, (2)
diastolic volumes, (3) ejection fraction, (4) cardiac index, (5)
pulmonary artery wedge pressure and (6) systemic vascular resis-
tance during treatment with coenzyme Q (dark shading) and
placebo (light shading). The height of the boxes shows the
interquartile distance (the difference between the third quartile of
the data and the first quartile). The notch is shown at the median
of the data, and the whiskers extend to the extreme values of the
data or 1.5 times the interquartile distance from the center,
whichever is less.
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ventricular ejection fraction. This was despite an increase in
plasma levels of coenzyme Q to more than twice basal
values.
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Figure 2. Box-and-whisker plots of left ventricular ejection frac-
tion (y axis) during treatment with placebo and coenzyme Q, with
line plots showing paired values for each subject.
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